GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (FRA:DPM) » Definitions » Shiller PE Ratio

Sumitomo Pharma Co (FRA:DPM) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Sumitomo Pharma Co Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sumitomo Pharma Co Shiller PE Ratio Historical Data

The historical data trend for Sumitomo Pharma Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Shiller PE Ratio Chart

Sumitomo Pharma Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.31 24.43 13.16 11.05 -

Sumitomo Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.05 10.18 9.74 11.71 -

Competitive Comparison of Sumitomo Pharma Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Shiller PE Ratio falls into.



Sumitomo Pharma Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sumitomo Pharma Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Sumitomo Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.049/107.2000*107.2000
=-3.049

Current CPI (Mar. 2024) = 107.2000.

Sumitomo Pharma Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.104 98.000 0.114
201409 0.109 98.500 0.119
201412 0.124 97.900 0.136
201503 -0.069 97.900 -0.076
201506 0.108 98.400 0.118
201509 0.136 98.500 0.148
201512 0.192 98.100 0.210
201603 0.027 97.900 0.030
201606 0.178 98.100 0.195
201609 0.056 98.000 0.061
201612 0.384 98.400 0.418
201703 0.036 98.100 0.039
201706 0.497 98.500 0.541
201709 0.395 98.800 0.429
201712 -0.027 99.400 -0.029
201803 0.184 99.200 0.199
201806 0.298 99.200 0.322
201809 0.243 99.900 0.261
201812 0.239 99.700 0.257
201903 0.174 99.700 0.187
201906 0.138 99.800 0.148
201909 0.502 100.100 0.538
201912 0.283 100.500 0.302
202003 -0.068 100.300 -0.073
202006 0.379 99.900 0.407
202009 0.385 99.900 0.413
202012 0.657 99.300 0.709
202103 -0.273 99.900 -0.293
202106 0.091 99.500 0.098
202109 0.615 100.100 0.659
202112 0.194 100.100 0.208
202203 0.194 101.100 0.206
202206 0.553 101.800 0.582
202209 -0.681 103.100 -0.708
202212 -0.198 104.100 -0.204
202303 -0.985 104.400 -1.011
202306 -0.639 105.200 -0.651
202309 -0.461 106.200 -0.465
202312 -0.801 106.800 -0.804
202403 -3.049 107.200 -3.049

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sumitomo Pharma Co  (FRA:DPM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sumitomo Pharma Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (FRA:DPM) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sumitomo Pharma Co (FRA:DPM) Headlines